Prognostic parameters of endometrial carcinoma.

[1]  C. Isacson,et al.  Endometrial Intraepithelial Carcinoma , 2000 .

[2]  H. Fox,et al.  The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma , 1987, British journal of obstetrics and gynaecology.

[3]  V. Abeler,et al.  Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. , 1990, Gynecologic oncology.

[4]  M. Sherman,et al.  Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. , 1995, Human pathology.

[5]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[6]  R. Young,et al.  The prognostic significance of adenomyosis in endometrial carcinoma. , 1984, Gynecologic oncology.

[7]  R. Kurman,et al.  Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage‐‐A gynecologic oncology group study , 1996, Cancer.

[8]  A. Berchuck,et al.  Favorable Survival Associated With Microsatellite Instability in Endometrioid Endometrial Cancers , 2001, Obstetrics and gynecology.

[9]  A. García,et al.  Molecular pathology of endometrial hyperplasia and carcinoma. , 2001, Human pathology.

[10]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[11]  H. Homesley,et al.  Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. , 1993, Gynecologic oncology.

[12]  S. Merajver,et al.  Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. , 1996, The American journal of pathology.

[13]  M. Sherman,et al.  Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. , 2000, The American journal of surgical pathology.

[14]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[15]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.

[16]  H. Uozaki,et al.  Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[17]  Mittal Kr,et al.  Diffusely infiltrating adenocarcinoma of the endometrium. A subtype with poor prognosis. , 1988 .

[18]  A. Berchuck,et al.  PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Kempson,et al.  Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.

[20]  H. Homesley,et al.  Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. , 1992, Gynecologic oncology.

[21]  V. Abeler,et al.  Endometrial adenocarcinoma with squamdus cell differentiation , 1992 .

[22]  R. Kempson,et al.  Primary mucinous adenocarcinoma of the endometrium: A clinicopathologic and histochemical study* , 1983, The American journal of surgical pathology.

[23]  V. Abeler,et al.  Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern , 1996, Cancer.

[24]  Y. Taketani,et al.  PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  P. O'Brien,et al.  Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. , 1990, American journal of obstetrics and gynecology.

[26]  P. Schwartz,et al.  Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. , 1990, American journal of clinical pathology.

[27]  R. Kurman,et al.  Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. , 1992, Gynecologic oncology.

[28]  R. Kurman,et al.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study , 1991 .

[29]  J. Williams,et al.  Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. , 1999, Experimental and molecular pathology.

[30]  V. Abeler,et al.  Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population , 1991, International Journal of Gynecologic Cancer.

[31]  M. Merino,et al.  Uterine papillary serous carcinoma , 1987, Obstetrics and gynecology.

[32]  N. Sneige,et al.  The Prognostic Significance of Peritoneal Cytology for Stage I Endometrial Cancer , 1989, Obstetrics and gynecology.

[33]  K. Fujita,et al.  Adenocarcinomas arising from uterine adenomyosis: a report of four cases. , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[34]  Manel Esteller,et al.  MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas , 1998, Oncogene.

[35]  B. Sorbe,et al.  DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma. , 1990, Gynecologic oncology.

[36]  Kathleen R. Cho,et al.  Microsatellite instability in endometrial carcinoma. , 1994, Oncogene.

[37]  H. Lynch,et al.  Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome) , 1996, International journal of cancer.

[38]  G. Eltabbakh,et al.  Survival of women with surgical stage II endometrial cancer. , 1999, Gynecologic oncology.

[39]  M. Piver,et al.  Prognostic significance of the extent of cervical involvement by endometrial cancer. , 1991, Gynecologic oncology.

[40]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[41]  R. Kempson,et al.  Ciliated Carcinoma—A Variant of Endometrial Adenocarcinoma: A Report of 10 Cases , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[42]  X. Matías-Guiu,et al.  CTNNB1 mutations and β-catenin expression in endometrial carcinomas , 2002 .

[43]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[44]  E. Silva,et al.  Serous carcinoma in endometrial polyps. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[45]  J. Herman,et al.  Abnormalities of the APC/β-catenin pathway in endometrial cancer , 2002, Oncogene.

[46]  P. Disaia,et al.  Risk factors and recurrent patterns in Stage I endometrial cancer. , 1985, American journal of obstetrics and gynecology.

[47]  W. Lawrence,et al.  Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases. , 1990, Gynecologic oncology.

[48]  D. O'connor,et al.  An analysis of two versus three grades for endometrial carcinoma. , 1999, Gynecologic oncology.

[49]  A. Lindgren,et al.  Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[50]  R. Kurman,et al.  A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. , 1997, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[51]  A. Markoe,et al.  The prognostic significance of surgical staging for carcinoma of the endometrium. , 1992 .

[52]  G. Wagenius,et al.  Prognostic Significance of Proliferation in Endometrial Adenocarcinomas: A Multivariate Analysis of Clinical and Flow Cytometric Variables , 1991, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[53]  R. Boronow.  Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge--a personal perspective. , 1997, Gynecologic oncology.

[54]  M. Carcangiu,et al.  Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. , 1992, Gynecologic oncology.

[55]  S. Silverberg.  Problems in the Differential Diagnosis of Endometrial Hyperplasia and Carcinoma , 2000, Modern Pathology.

[56]  A. Dursun,et al.  Angiogenesis, p53, and bcl‐2 Expression as Prognostic Indicators in Endometrial Cancer: Comparison with Traditional Clinicopathologic Variables , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[57]  C. Aquino-Parsons,et al.  Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. , 1998, Gynecologic oncology.

[58]  M. Hendrickson,et al.  Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. , 1999, The American journal of surgical pathology.

[59]  D. Herbold,et al.  The significance of squamous differentiation in endometrial carcinoma. Data from a gynecologic oncology group study , 1991, Cancer.

[60]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.

[61]  X. Matías-Guiu,et al.  PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. , 2000, Human pathology.

[62]  X. Matías-Guiu,et al.  Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. , 1998, Human pathology.

[63]  R. Kurman,et al.  Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. , 1998, Human pathology.

[64]  P. Vacek,et al.  Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. , 1994, Gynecologic oncology.

[65]  K. Geisinger,et al.  Endometrial adenocarcinoma: A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors , 1986, Cancer.

[66]  B. Karlan,et al.  HER‐2/neu, p53, and DNA Analyses as Prognosticators for Survival in Endometrial Carcinoma , 1995, Obstetrics and gynecology.

[67]  D. Gal,et al.  The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma , 1992, Cancer.

[68]  D. Schmidt,et al.  Distinction between endometrial and endocervical adenocarcinoma. , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[69]  L. Akslen,et al.  Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  T. Nikaido,et al.  Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. , 2003, Human pathology.

[71]  Secretory Adenocarcinoma of the Endometrium , 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[72]  J A Blessing,et al.  Surgical Staging in Endometrial Cancer: Clinical—Pathologic Findings of a Prospective Study , 1984, Obstetrics and gynecology.

[73]  S. Yoshida,et al.  Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. , 2003, Endocrine-related cancer.

[74]  H. Watari,et al.  Bcl‐2 expression and prognosis of patients with endometrial carcinoma , 1998, International journal of cancer.

[75]  R. Kurman,et al.  Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well‐differentiated carcinoma , 1982 .

[76]  L. Jordan,et al.  Clinicopathological study of the pattern and significance of cervical involvement in cases of endometrial adenocarcinoma , 2002, International Journal of Gynecologic Cancer.

[77]  X. Matías-Guiu,et al.  K‐ras mutations in endometrial carcinomas with microsatellite instability , 2001, The Journal of pathology.

[78]  M. Pieretti,et al.  Loss of heterozygosity in usual and special variant carcinomas of the endometrium. , 1997, Human pathology.

[79]  R. Kempson,et al.  Adenocarcinoma of the endometrium analysis of 256 cases with disease limited to the uterine corpus: Treatment comparisons , 1983 .

[80]  L. Kilgore,et al.  Surgical staging in endometrial cancer. , 2006, Oncology.

[81]  M. Saegusa,et al.  β-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis , 2001, British Journal of Cancer.

[82]  J. Baak,et al.  Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma , 1989, Cancer.

[83]  P. Roche,et al.  Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. , 2000, Gynecologic oncology.

[84]  V. Abeler,et al.  Endometrial adenocarcinoma in Norway. A study of a total population , 1991, Cancer.

[85]  Kathleen R. Cho,et al.  p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. , 1997, The American journal of pathology.

[86]  K. Podratz,et al.  Flow cytometric DNA analysis of stage I endometrial carcinoma. , 1989, Gynecologic oncology.

[87]  W. Sauerbrei,et al.  Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. , 1995, Gynecologic oncology.

[88]  P. Clement,et al.  Endometrial Endometrioid Adenocarcinoma With a Deceptive Pattern of Spread to the Uterine Cervix: A Manifestation of Stage IIB Endometrial Carcinoma Liable to Be Misinterpreted as an Independent Carcinoma or a Benign Lesion , 2003, The American journal of surgical pathology.

[89]  R. Kurman,et al.  The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study , 1995, Cancer.

[90]  T. Mori,et al.  Endometrial carcinoma: nontumor factors in prognosis. , 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[91]  M. Piver,et al.  Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma , 1990, Gynecologic oncology.

[92]  D. Herbold,et al.  The significance of squamous differentiation in endometrial carcinoma , 1988 .

[93]  C. Holinka,et al.  Progesterone receptors in two groups of endometrial carcinoma , 1986, Cancer.

[94]  R. Bentley,et al.  Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. , 1998, The American journal of surgical pathology.

[95]  S. Hirohashi,et al.  Beta-catenin mutation in carcinoma of the uterine endometrium. , 1998, Cancer research.

[96]  W. Christopherson,et al.  Carcinoma of the endometrium: I. A clinicopathologic study of clear‐cell carcinoma and secretory carcinoma , 1982 .

[97]  D. Gal,et al.  Lymphvascular space involvement--a prognostic indicator in endometrial adenocarcinoma. , 1991, Gynecologic oncology.

[98]  R. Kurman,et al.  A Binary Architectural Grading System for Uterine Endometrial Endometrioid Carcinoma Has Superior Reproducibility Compared With FIGO Grading and Identifies Subsets of Advance-Stage Tumors With Favorable and Unfavorable Prognosis , 2000, The American journal of surgical pathology.

[99]  E. Lerma,et al.  Uterine Papillary Serous Adenocarcinoma , 1994 .

[100]  M. Nucci,et al.  Distinction Between Endometrial and Endocervical Adenocarcinoma: An Immunohistochemical Study , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[101]  K. Geisinger,et al.  Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium , 1986, Cancer.

[102]  M. Hendrickson,et al.  Proposed Criteria for the Diagnosis of Well‐Differentiated Endometrial Carcinoma: A Diagnostic Test for Myoinvasion , 1995, The American journal of surgical pathology.

[103]  V. Sumathi,et al.  A Panel of Immunohistochemical Stains, Including Carcinoembryonic Antigen, Vimentin, and Estrogen Receptor, Aids the Distinction Between Primary Endometrial and Endocervical Adenocarcinomas , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[104]  B. Goff,et al.  Assessment of depth of myometrial invasion in endometrial adenocarcinoma. , 1990, Gynecologic oncology.

[105]  K. Barwick,et al.  Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. , 1993, Gynecologic oncology.

[106]  P. Schwartz,et al.  Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. , 1990, American journal of clinical pathology.

[107]  E. Lerma,et al.  Uterine papillary serous adenocarcinoma. A 10‐case study of p53 and c‐erbB‐2 expression and DNA content , 1994, Cancer.

[108]  C. Kosary.  FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. , 1994, Seminars in surgical oncology.

[109]  T. Kaku,et al.  Association of endometrial epithelial metaplasias with endometrial carcinoma and hyperplasia in Japanese and American women. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[110]  E. Wilkinson,et al.  Endometrial Papillary Adenocarcinomas: Two Clinicopathological Types , 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[111]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[112]  R. Kempson,et al.  Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables. , 1982, Gynecologic oncology.

[113]  R. Scully,et al.  Unusual Epithelial and Stromal Changes in Myoinvasive Endometrioid Adenocarcinoma: A Study of Their Frequency, Associated Diagnostic Problems, and Prognostic Significance , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[114]  J. van Nagell,et al.  The prognostic significance of lymph‐vascular space invasion in stage I endometrial cancer , 1985, Cancer.